undamentalytics Newsletter
Sign in

Annovis Bio, Inc. cash flow statement

In fiscal 2025, Annovis Bio, Inc.'s operations generated −$25.6m of cash.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−0−4−9−17−40−22−26−43
Stock-based pay02595423
Shares issued—1247—1719——

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Annovis Bio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Annovis Bio, Inc.